Syndax Pharmaceuticals (SNDX) Misses Q3 EPS by 13c

Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q3 EPS of ($0.84), $0.13 worse than the analyst estimate of ($0.71). Revenue for the quarter came in at $305 thousand versus the consensus estimate of $100 thousand.

For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.

You May Also Be Interested In

• Broadcom credit risk measures rise amid AI financing deals
• Howmet Aerospace Inc. (HWM) PT Raised to $328 at Bernstein SocGen Group
• Buffalo airport blames circuit fault, not shortage, for 3 flight delays